Oral Honokiol-loaded solid lipid nanoparticles: A shielding nanotherapeutic strategy to attenuate STZ-induced type 1 diabetes via targeted modulation of oxidative stress and apoptotic signaling
Molecular and Cellular Endocrinology · 2026-07 · 617 · 112785
DOI: 10.1016/j.mce.2026.112785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2026-07. Verfasst von Tehmina Bibi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacological Sciences Research Lab, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, 45320, Pakistan; D…. Hauptthemen laut MEDLINE: Biphenyl Compounds, Oxidative Stress, Apoptosis, Lignans. Die Arbeit nennt 81 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This study aimed to analyze the protective effect of Honokiol-loaded oral solid lipid nanoparticles (Honokiol-SLNs) on pancreatic beta-cells (β-cells) in an experimental model of type 1 diabetes. Streptozotocin (STZ) injection (150 mg/kg) was used to induce diabetes in male Swiss mice. Honokiol-SLNs were administered daily during the 28-day experimental phase, commencing after the onset of hyperglycemia. After the experiment, the activity of β-cells, apoptosis, oxidative stress, and inflammation were assessed using pancreatic tissue and blood. In vitro experiments have preliminarily validated the ability of Honokiol-SLNs to inhibit α-amylase and α-glucosidase, suggesting potential anti-diabetic effects. Furthermore, administering Honokiol-SLNs (5mg/kg) to animals significantly reduced blood glucose levels, as well as food and water consumption, and increased body weight, serum insulin levels, and pancreatic insulin levels. Additionally, it was demonstrated that Honokiol-SLNs inhibited apoptosis by reducing the expression of cleaved caspase-3, exhibited beneficial antioxidant properties by enhancing nuclear factor erythroid 2-related factor 2 (Nrf2), and mitigated inflammation by suppressing nuclear factor kappa B (NF-κB). Honokiol-SLNs substantially reversed pancreatic histological and spectroscopic aberrations. Moreover, reduced oxido-nitrosative stress and pro-inflammatory cytokines correlated with raised antioxidant capacity. These results imply that by suppressing oxidative stress and triggering antioxidant, anti-inflammatory, and anti-apoptotic actions, Honokiol-SLNs may shield pancreatic β-cells and enhance their function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacological Sciences Research Lab, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, 45320, Pakistan; Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam Un…
- Department of Zoology, Government College University, Lahore, Punjab, Pakistan.
Zitieren
APA
Bibi, T., Bano, S., Shabbir, A., & Khan, S. (2026). Oral Honokiol-loaded solid lipid nanoparticles: A shielding nanotherapeutic strategy to attenuate STZ-induced type 1 diabetes via targeted modulation of oxidative stress and apoptotic signaling. Molecular and Cellular Endocrinology, 617, 112785. https://doi.org/10.1016/j.mce.2026.112785
Vancouver
Bibi T, Bano S, Shabbir A, Khan S. Oral Honokiol-loaded solid lipid nanoparticles: A shielding nanotherapeutic strategy to attenuate STZ-induced type 1 diabetes via targeted modulation of oxidative stress and apoptotic signaling. Molecular and Cellular Endocrinology. 2026;617:112785. doi:10.1016/j.mce.2026.112785
BibTeX
@article{Bibi2026,
author = {Bibi, Tehmina and Bano, Shahar and Shabbir, Arifa and Khan, Salman},
title = {Oral Honokiol-loaded solid lipid nanoparticles: A shielding nanotherapeutic strategy to attenuate STZ-induced type 1 diabetes via targeted modulation of oxidative stress and apoptotic signaling},
journal = {Molecular and Cellular Endocrinology},
year = {2026},
volume = {617},
pages = {112785},
doi = {10.1016/j.mce.2026.112785}
}
EUVIMED